Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
HOME > ARCHIVE
ARCHIVE
- Prof. Yamanaka, Dr Kondo of PMDA Discuss Toxicity Assessment for iPS Cells-Derived Products
March 7, 2011
- Kyorin Licenses Aclidinium from Almirall
March 7, 2011
- Merck Serono Withdraws MAA for Cladribine
March 7, 2011
- Yakult Ties Up with Proacta to Commercialize Anticancer Drugs
March 7, 2011
- Gov't Bought Vaccines for New Type Flu at \905.50 per Dose
March 7, 2011
- Sanofi-aventis to Transfer Long-Listed Products to Nichi-Iko
March 7, 2011
- Takeda to Develop New Drugs with Unmet Medical Needs at New Research Center
March 7, 2011
- Mochida Recalls Its Generic Heparin Ca
March 7, 2011
- Shionogi to Create GDO to Accelerate Global Development
March 7, 2011
- New Drugs Improve Range of Options for Osteoporosis: 3
March 7, 2011
- PIII Results for Afinitor Published in NEJM
March 7, 2011
- Korosho Approves Norspan, NorLevo after One-Month Delay
March 7, 2011
- Avastin Prolongs PFS in Ovarian Cancer
March 7, 2011
- Nesina Approved for Coadministration with SU and BG: Takeda
March 7, 2011
- JAMS Announces GLs for COI Management
March 7, 2011
- Xeloda Approved for Advanced/Recurrent Stomach Cancer: Chugai
March 7, 2011
- 8 Companies to Withdraw Generic Versions of Dasen
March 7, 2011
- Warfarin Approved for Pediatric Use: Eisai
March 7, 2011
- Korosho Calls on Generic Firms to Apply for New Indications Based on Data from Public Domain
March 7, 2011
- HbA1c to Be Reported in Int'l Units from April 2012 at the Earliest
March 7, 2011
ページ
Japan’s pharmaceutical industry could be on the verge of gaining a stronger voice in the Central Social Insurance Medical Council…
Let’s face it: in today’s world, changing jobs is a normal part of a successful career. But if it’s so normal, why does it feel so hard? For many people, the idea of leaving their current role brings a heavy…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…